指南与共识肺结节与肺癌

多学科肿瘤委员会在局部晚期非小细胞肺癌临床分期与治疗推荐中的差异

Variation Between Multidisciplinary Tumor Boards in Clinical Staging and Treatment Recommendations for Patients With Locally Advanced Non-small Cell Lung Cancer.
指南 / 共识 · Chest · 2020-07-30

研究让11个多学科肿瘤委员会(MDT)分别评估相同的10例病理IIIA期NSCLC患者(共110次评估),使用Randolph自由边际多评分者kappa检验一致性。结果显示T分期、N分期、总体TNM分期和治疗推荐的kappa分别为0.55、0.59、0.53和0.44,提示MDT间存在高度差异。

要点

  • 同一批IIIA期NSCLC患者在不同MDT间的分期和治疗推荐一致性仅为中等至较低。
  • T分期差异主要见于怀疑侵犯周围结构的患者,影响诱导治疗及类型推荐。
  • N1与N2的区分是N分期不一致的重要来源,且MDT提出了大量额外诊断检查。

核心结论

  • 不同医院MDT对IIIA期NSCLC患者的分期和治疗存在高度差异,应努力追求更一致性。

研究设计与样本

  • 11个MDT各自在周会上评估相同的10例病理IIIA期NSCLC患者,共110次评估,患者为故意选取的疑难病例。
  • 所有MDT获得完全相同的临床信息和图像,采用Randolph自由边际多评分者kappa检验一致性。

主要发现

  • T分期一致性kappa为0.55(95%CI 0.34-0.75),N分期为0.59(95%CI 0.35-0.83)。
  • 总体TNM分期一致性kappa为0.53(95%CI 0.35-0.72),治疗推荐一致性kappa为0.44(95%CI 0.32-0.56)。
  • T分期最大差异见于怀疑侵犯周围结构的患者,影响诱导治疗及类型推荐。
  • N分期中N1与N2的区分是MDT间不一致的重要来源,甚至2例患者间M分期也存在差异。
  • MDT提出了广泛的额外诊断检查建议。

临床怎么用

  • 临床应意识到IIIA期NSCLC的MDT分期和治疗推荐存在显著中心间差异。
  • 对怀疑侵犯周围结构或N1/N2鉴别困难的患者,需更规范评估以减少差异。

局限性

  • 患者为故意选取的疑难病例,可能高估真实世界中的差异程度。
  • 样本量较小(10例患者、11个MDT),结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate diagnosis and staging are crucial to ensure uniform allocation to the optimal treatment methods for non-small cell lung cancer (NSCLC) patients, but may differ among multidisciplinary tumor boards (MDTs). Discordance between clinical and pathologic TNM stage is particularly important for patients with locally advanced NSCLC (stage IIIA) because it may influence their chance of allocation to curative-intent treatment. We therefore aimed to study agreement on staging and treatment to gain insight into MDT decision-making. RESEARCH QUESTION: What is the level of agreement on clinical staging and treatment recommendations among MDTs in stage IIIA NSCLC patients? STUDY DESIGN AND METHODS: Eleven MDTs each evaluated the same 10 pathologic stage IIIA NSCLC patients in their weekly meeting (n = 110). Patients were selected purposively for their challenging nature. All MDTs received exactly the same clinical information and images per patient. We tested agreement in cT stage, cN stage, cM stage (TNM 8th edition), and treatment proposal among MDTs using Randolph's free-marginal multirater kappa. RESULTS: Considerable variation among the MDTs was seen in T staging (κ, 0.55 [95% CI, 0.34-0.75]), N staging (κ, 0.59 [95% CI, 0.35-0.83]), overall TNM staging (κ, 0.53 [95% CI, 0.35-0.72]), and treatment recommendations (κ, 0.44 [95% CI, 0.32-0.56]). Most variation in T stage was seen in patients with suspicion of invasion of surrounding structures, which influenced such treatment recommendations as induction therapy and type. For N stage, distinction between N1 and N2 disease was an important source of discordance among MDTs. Variation occurred between 2 patients even regarding M stage. A wide range of additional diagnostics was proposed by the MDTs. INTERPRETATION: This study demonstrated high variation in staging and treatment of patients with stage IIIA NSCLC among MDTs in different hospitals. Although some variation may be unavoidable in these challenging patients, we should strive for more uniformity.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Hoeijmakers F, Heineman DJ, Daniels JM, et al. Variation Between Multidisciplinary Tumor Boards in Clinical Staging and Treatment Recommendations for Patients With Locally Advanced Non-small Cell Lung Cancer. Chest. 2020. PMID: 32738254. doi:10.1016/j.chest.2020.07.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。